State Street Corp Grows Stock Holdings in Applied Therapeutics, Inc. (NASDAQ:APLT)

State Street Corp raised its holdings in shares of Applied Therapeutics, Inc. (NASDAQ:APLT) by 123.1% during the third quarter, HoldingsChannel reports. The fund owned 3,694,607 shares of the company’s stock after purchasing an additional 2,038,724 shares during the quarter. State Street Corp’s holdings in Applied Therapeutics were worth $31,404,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Principal Financial Group Inc. bought a new stake in shares of Applied Therapeutics during the 2nd quarter valued at $54,000. Victory Capital Management Inc. purchased a new position in Applied Therapeutics during the 2nd quarter valued at about $54,000. SG Americas Securities LLC bought a new stake in shares of Applied Therapeutics during the second quarter valued at about $87,000. Algert Global LLC purchased a new stake in shares of Applied Therapeutics in the second quarter worth about $110,000. Finally, Intech Investment Management LLC bought a new position in shares of Applied Therapeutics in the third quarter valued at approximately $162,000. Hedge funds and other institutional investors own 98.31% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on APLT shares. Robert W. Baird lowered their target price on shares of Applied Therapeutics from $14.00 to $5.00 and set an “outperform” rating on the stock in a research note on Friday, November 29th. Leerink Partners increased their price objective on Applied Therapeutics from $11.00 to $14.00 and gave the stock an “outperform” rating in a research report on Thursday, September 19th. William Blair raised Applied Therapeutics to a “strong-buy” rating in a research note on Thursday, November 28th. UBS Group restated a “neutral” rating and issued a $2.00 target price (down from $13.00) on shares of Applied Therapeutics in a research note on Monday, December 2nd. Finally, Citigroup cut their price objective on Applied Therapeutics from $13.00 to $8.00 and set a “buy” rating for the company in a report on Friday, November 29th. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $6.10.

Applied Therapeutics Stock Down 13.7 %

Shares of APLT stock opened at $0.88 on Friday. The business has a 50-day moving average price of $6.63 and a two-hundred day moving average price of $6.14. Applied Therapeutics, Inc. has a 12-month low of $0.84 and a 12-month high of $10.62. The firm has a market cap of $102.40 million, a P/E ratio of -0.55 and a beta of 1.76.

Applied Therapeutics Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.